Joint PSI/EFSPI Pre-Clinical SIG Webinar: Mixed-Level OMARS Designs for Quantitative and Categorical Factors: Theory and Application

Joint PSI/EFSPI Visualisation SIG 'Wonderful Wednesday' Webinars

Our monthly webinar explores examples of innovative data visualisations relevant to our day to day work. Each month a new dataset is provided from a clinical trial or other relevant example, and participants are invited to submit a graphic that communicates interesting and relevant characteristics of the data.

PSI Webinar: Drug Development in Women's Health

The event will open with an overview on drug development in women’s health from a clinician perspective. This talk is followed by talks about statistical challenges when planning IVF studies and analysing the menstrual cycles.

PSI Webinar: Surrogacy

This webinar will provide an overview of surrogacy for licensing and reimbursement. In turn, the need of extensions of the SPIRIT and CONSORT statement will be defined and outlined, with case studies to support.

Joint PSI/EFSPI Pre-Clinical SIG Webinar: Virtual Control Groups in Toxicity Studies

Lea Vaas will present how replacement of concurrent control animals by Virtual Control Groups (VCGs) in systemic toxicity studies may help in contributing to the 3R's principle of animal experimentation: Reduce, Refine, Replace.

Joint PSI/EFSPI Data Science SIG Webinar: Developing Digital Measures (Digital Biomarkers) in Drug Development – insights from Mobilise D consortium

We will share a brief overview of what Mobilise D is and why it is an important step stone in the development of digital biomarkers, and how Mobilise D outputs can be relevant for you.

PSI Career Young Virtual Event (Q2 2024)

This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.

PSI Webinar: Development of Gene Therapies: Strategic, Scientific, Regulatory and Access Considerations

This webinar will cover the history of cell/gene therapy, major regulatory advances, the role of quantitative scientists in drug development of these novel therapeutics, and discuss opportunities for innovation and product advancement.

PSI Career Young Virtual Event (Q3 2024)

This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.

PSI Introduction to Industry Training (ITIT) Course - 2024/2025

An introductory course giving an overview of the pharmaceutical industry and the drug development process as a whole, aimed at those with 1-3 years' experience. It comprises of six 2-day sessions covering a range of topics including Research and Development, Toxicology, Data Management and the Role of a CRO, Clinical Trials, Reimbursement, and Marketing.

PSI Career Young Virtual Event (Q4 2024)

This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.

Speaker	Biography	Abstract
Peter Goos	Peter Goos is a full professor at the Faculty of Bio-Science Engineering of KU Leuven, and at the Faculty of Business and Economics of the University of Antwerp, where he teaches various introductory and advanced courses on statistics and probability. His main research area is the statistical design and analysis of experiments. Besides numerous influential articles in various kinds of scientific journals, he published the books The Optimal Design of Blocked and Split-Plot Experiments, Optimal Experimental Design: A Case-Study Approach, Statistics with JMP: Graphs, Descriptive Statistics and Probability and Statistics with JMP: Hypothesis Tests, ANOVA and Regression. For his work, Peter Goos has received four Shewell Awards, two Lloyd S. Nelson Awards, a Brumbaugh Award and the Youden Award of the American Society for Quality, the Ziegel Award and the Statistics in Chemistry Award from the American Statistical Association, and the Young Statistician Award of the European Network for Business and Industrial Statistics (ENBIS). Peter Goos is known for this ability to introduce new design of experiments concepts in an accessible fashion to non-academics.	OMARS Designs: Factor Screening and Response Surface Optimization in a Single Step The family of orthogonal minimally aliased response surface designs or OMARS designs bridges the gap between the small definitive screening designs and classical response surface designs, such as central composite designs and Box-Behnken designs. The initial OMARS designs involve three levels per factor and allow large numbers of quantitative factors to be studied efficiently using limited numbers of experimental tests. Many of the OMARS design possess good projection properties and offer better powers for quadratic effects than definitive screening designs with similar numbers of runs. Therefore, OMARS designs offer the possibility to perform a screening experiment and a response surface experiment in a single step, and thereby offer the opportunity to speed up innovation and process improvement. A technical feature of the initial OMARS designs is that they study every quantitative factor at its middle level the same number of times. In this talk, we relax this constraint and arrange the designs in blocks, and thereby broaden the family of OMARS designs tremendously. We also present a successful application of OMARS designs in the pharmaceutical and chemical industries.

Event